Jella An, MD
Ophthalmology · Columbia, MONPI 1033567763
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (41.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Alcon at 37.3% of the total. 2025 is the largest year on record at $70,033, more than ten times the $5,934 reported in 2019. Among ophthalmology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 409 payments — averaging $406.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$62K
- Sight Sciences, Inc.$25K
- Iridex Corporation$23K
- Aerie Pharmaceuticals, Inc.$18K
- NEW World Medical,inc.$15K
- AbbVie$13K
- plus $10K from 12 others
Across 14 payments — averaging $4960.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$64K
- Alcon Research LLC$4K
- Ivantis, Inc$2K
What the payments were for
- Consulting fees$68,62841%
- Speaking & faculty fees$67,51741%
- Travel & lodging$15,90310%
- Food & beverage$14,1068%
- Gifts$1250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 119 | $61,963 |
| Sight Sciences, Inc. | 42 | $25,318 |
| Iridex Corporation | 15 | $23,391 |
| Aerie Pharmaceuticals, Inc. | 32 | $18,277 |
| NEW World Medical,inc. | 55 | $14,514 |
| AbbVie(2 entities) | 68 | $12,658 |
| Ivantis, Inc | 32 | $4,532 |
| Carl Zeiss Meditec USA, Inc. | 5 | $1,651 |
| Bausch & Lomb Americas Inc. | 13 | $1,520 |
| Alcon Research LLC | 1 | $1,000 |
| Glaukos Corporation | 11 | $580 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $251 |
| Dompe US, Inc. | 3 | $171 |
| Sun Pharmaceutical Industries Inc. | 3 | $154 |
| Recordati_rare_diseases_inc. | 1 | $124 |
| Carl Zeiss Meditec, Inc. | 1 | $92 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $60 |
| Novartis | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hydrus Microstent$58,729
- Voyager DSLT$48,381
- OMNI(R) SURGICAL SYSTEM (US)$24,231
- Rhopressa$17,830
- Rocklatan$17,830
- SION SURGICAL INSTRUMENT$14,995
- Ahmed Glaucoma Valve$11,649
- Kahook Dual Blade$11,649
- XEN GLAUCOMA TREATMENT SYSTEM$8,025
- Hydrus$2,910
- Streamline Surgical System$2,202
- ARTEVO 800$1,533
- CIRRUS HD-OCT$1,533
- IOLMaster 700$1,533
- VERACITY SURGICAL$1,533
- VisuMax$1,533
- Clearpath$1,514
- Streamline$1,514
- SIMBRINZA$1,400
- Viscoat$1,000
How this compares
$166,279 in reported general payments places this provider in the 95th percentile of 286 ophthalmology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 47 | $17,778 |
| CombiganBrimonidine Tartrate/Timolol | 27 | $11,930 |
| RhopressaNetarsudil Mesylate | 21 | $10,474 |
| RocklatanNetarsudil Mesylat/Latanoprost | 14 | $9,879 |
| TafluprostTafluprost/Pf | 49 | $9,475 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 26 | $6,186 |
| Latanoprost | 503 | $5,272 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 27 | $5,262 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 200 | $4,220 |
| Prednisolone Acetate | 82 | $4,009 |
| Travoprost | 13 | $3,929 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 22 | $2,345 |
| Bromfenac Sodium | 14 | $1,815 |
| Bimatoprost | 11 | $1,671 |
| Brimonidine Tartrate | 92 | $1,245 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan | $12,658 | $29,70774 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $18,277 | $20,35335 claims |
| AlconSimbrinza | $61,963 | $5,26227 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 286 ophthalmology providers in Missouri.
Other ophthalmology in Columbia
- Mai PhamColumbia$17K
- John McCannColumbia$8K
- Steven SilversteinKansas City$872K
- Ranjan MalhotraSaint Louis$809K
- Nancy HolekampChesterfield$768K
- Jay PeposeChesterfield$516K
- Gregg BerdySaint Louis$360K
- Joseph GiraDes Peres$174K
- Joseph TauberKansas City$174K
- Shachar TauberSpringfield$150K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.